Finland· FI-REL-REL58818
Vyvgart
A efgartigimod alfa product containing efgartigimod alfa, registered in Finland by Argenx. The same ATC class is registered in 7 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Efgartigimod alfa is registered in 7 of 19 countries.
Countries holding a registration under ATC L04AL01 (efgartigimod alfa), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 5 of them publish a price we can compare per daily dose
Efgartigimod alfa · ATC L04AL01
7 / 19 countries
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Efgartigimod alfa
- Manufacturer
- Argenx
- Country
- Finland (FI)
- ATC code
- L04AL01
- ATC class
- Efgartigimod alfa
- Defined daily dose
- 4 g, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Efgartigimod alfa in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumVyvgart 20 mg/mlArgenx
- SwitzerlandVyvgart 400 mg/20ml, solution à diluer pour perfusionargenx Switzerland SA
- CzechiaVYVGARTargenx BV, Gent
- IrelandVyvgart 20 mg/mL concentrate for solution for infusionArgenx
- IcelandVyvgartArgenx BV
- PolandVyvgartargenx BV
- SwedenVyvgart 20 mg/ml Koncentrat till infusionsvätska, lösningArgenx
- SpainVYVGART 1.000 MG SOLUCION INYECTABLEArgenx B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vyvgart
- Liechtenstein · Vyvgart
- Norway · Vyvgart
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/eaa7d9ad-41a1-412a-9a5b-9c4f68898ac1 GET /v1/drugs/eaa7d9ad-41a1-412a-9a5b-9c4f68898ac1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "infuusiokonsentraatti, liuosta varten",
"route": "Laskimoon",
"ddd_unit": null,
"strength": "20 mg/ml",
"atc_label": "efgartigimodi alfa",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/22/1674/001",
"fimea_rel_id": "REL58818",
"authorised_at": "2022-08-10"
}See everything about efgartigimod alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.